Skip to main content
    S

    Sagimet Biosciences Inc. Series A Common Stock (SGMT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.13
    -0.09 (-0.88%)

    Market Cap: $735.18M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Sagimet Biosciences Inc. Series A Common Stock (SGMT) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Sagimet Biosciences Inc. Series A Common Stock reported EPS of -$0.31, below the -$0.25 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    69%(9/13)
    Avg Surprise
    +13.20%

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.29
    Range-$0.35 - -$0.22
    14 analysts
    Revenue Consensus
    N/A
    RangeN/A
    13 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.27
    Range-$0.30 - -$0.22
    4 analysts
    EPS Estimate DriftChange to current
    90d ago-$0.33+17.4%
    60d ago-$0.34+19.1%
    30d ago-$0.29+6.0%
    7d ago-$0.29+6.0%
    Current-$0.27
    Revenue Consensus
    $2.96M
    Range$930.00K - $5.00M
    2 analysts

    Next Report

    SGMT's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    Earnings History

    Of the 13 quarters below that had an estimate, SGMT beat 9 and missed 4. The widest gap in the table came in the quarter ended Sep 30, 2023, when EPS landed 56.25% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Sep 30, 2026-$0.31-$0.25-$0.34 - -$0.20-24.00%MissN/A11N/ANov 12, 2026
    Jun 30, 2026-$0.26-$0.28-$0.33 - -$0.16+7.14%BeatN/A97 up, 0 downAug 11, 2026
    Mar 31, 2026-$0.33-$0.35-$0.48 - -$0.21+5.71%BeatN/A8N/AMay 12, 2026
    Dec 31, 2025-$0.29-$0.40-$0.45 - -$0.23+27.79%BeatN/A80 up, 0 downMar 11, 2026
    Sep 30, 2025-$0.40-$0.39-$0.58 - -$0.33-2.56%MissN/A8N/ANov 13, 2025
    Jun 30, 2025-$0.32-$0.50-$0.64 - -$0.24+36.00%BeatN/A96 up, 0 downAug 13, 2025
    Mar 31, 2025-$0.56-$0.71-$1.00 - -$0.54+21.13%BeatN/A63 up, 0 downMay 8, 2025
    Dec 31, 2024-$0.50-$0.65-$0.83 - -$0.37+23.08%BeatN/A60 up, 0 downMar 12, 2025
    Sep 30, 2024-$0.45-$0.40-$0.52 - -$0.29-12.50%MissN/A60 up, 0 downNov 14, 2024
    Jun 30, 2024-$0.25-$0.35-$0.40 - -$0.23+28.57%BeatN/A60 up, 0 downAug 14, 2024
    Mar 31, 2024-$0.23-$0.38-$0.51 - -$0.32+39.47%BeatN/A60 up, 0 downMay 15, 2024
    Dec 31, 2023-$0.78-$0.58-$0.71 - -$0.42-34.48%MissN/A40 up, 0 downMar 25, 2024
    Sep 30, 2023-$0.35-$0.80-$1.58 - -$0.45+56.25%BeatN/A40 up, 0 downNov 13, 2023
    Jun 30, 2023-$35.80-$0.52-$0.54 - -$0.44N/AN/AN/A40 up, 0 downJul 14, 2023
    Mar 31, 2023-$0.44N/AN/AN/AN/AN/AN/AN/AMay 31, 2023
    Last 15 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.57, after -$1.43 the year before. It was -$37.37 for the year ended Dec 31, 2023, the oldest of the 3 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.57N/A
    Dec 31, 2024-$1.43N/A
    Dec 31, 2023-$37.37N/A

    Frequently Asked Questions About SGMT

    Did SGMT beat earnings estimates last quarter?

    No. Sagimet Biosciences Inc. Series A Common Stock reported EPS of -$0.31 for the quarter ended Sep 30, 2026, below the -$0.25 estimate by 24.00%.

    What EPS do analysts expect from SGMT next quarter?

    The consensus EPS estimate for Sagimet Biosciences Inc. Series A Common Stock for the quarter ending Dec 31, 2026 is -$0.29 from 14 analysts, with estimates from -$0.35 to -$0.22.

    How often does SGMT beat earnings estimates?

    Sagimet Biosciences Inc. Series A Common Stock beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +11.79%.